<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00629031</url>
  </required_header>
  <id_info>
    <org_study_id>KAMRC PSD</org_study_id>
    <nct_id>NCT00629031</nct_id>
  </id_info>
  <brief_title>An Open Lable Randomised Study to Assess the Safety and Efficacy of Short Course Paromomycin in Visceral Leishmaniasis</brief_title>
  <official_title>An Open Lable Randomised Two -Arm Study to Assess the Safety and Efficacy of Paromomycin Administered Intramuscularly at Two Different Dosing Regimens (14 Days Versus 21 Days) for the Treatment of Indian Visceral Leishmaniasis (VL)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Banaras Hindu University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Banaras Hindu University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      It is a randomized, double-blind, multi-center, two-arm study intended to assess the safety&#xD;
      and efficacy of three different doses/dose regimens of paromomycin administered&#xD;
      intramuscularly as follows: 11 mg/kg/day for 14 days and 11 mg/kg/day for 21 days for the&#xD;
      treatment of visceral leishmaniasis (VL) in India.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Paromomycin administered at a dose of 11 mg/kg/day IM for 21 days was previously demonstrated&#xD;
      by iOWH and WHO to be as effective as amphotericin B administered IV at a dose of 1&#xD;
      mg/kg/every other day for a total for a total of 15 doses over 30 days in the treatment of VL&#xD;
      in Bihar, India (protocol VLPM01) in a recently completed study (94.6% vs. 98.8% of subjects&#xD;
      were disease free at 6 months, respectively). This new study is being conducted to determine&#xD;
      whether similar or better efficacy and safety of IM paromomycin can be achieved with a&#xD;
      shorter duration of treatment (14 days rather than 21 days) administered for a shorter&#xD;
      duration (14 days rather than 21 days) than the regimen studied in the previous trial.&#xD;
&#xD;
      This shorter duration study will compare the initial and final cure (response to treatment)&#xD;
      rates in subjects with VL receiving paromomycin at the following doses and dose regimens:&#xD;
&#xD;
        -  Group A: paromomycin 11 mg/kg/day IM for 14 days&#xD;
&#xD;
        -  Group B: paromomycin 11 mg/kg/day IM for 21 days&#xD;
&#xD;
      Because compliance generally improves with shorter duration of therapy, and better treatment&#xD;
      compliance decreases the probability of the emergence of drug-resistant disease,&#xD;
      administration of higher daily doses of paromomycin for a shorter time may improve efficacy&#xD;
      without producing unacceptable toxicity. In addition, a treatment regimen of shorter duration&#xD;
      would cost less and be easier to administer.&#xD;
&#xD;
      The current study is designed to explore different doses and dose regimens of IM paromomycin&#xD;
      to determine the dose and dose regimen that should be recommended for first-line therapy for&#xD;
      treatment of VL, while maintaining the efficacy and safety.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>February 2008</start_date>
  <completion_date type="Actual">August 2008</completion_date>
  <primary_completion_date type="Actual">February 2008</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Final Cure</measure>
    <time_frame>6 months after the end of treatment</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Initial cure</measure>
    <time_frame>End of treatment</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">329</enrollment>
  <condition>Visceral Leishmaniasis</condition>
  <arm_group>
    <arm_group_label>2</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Paromomycin for 21 days @ 11mg/kg</description>
  </arm_group>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Paromomycin for 14 days @ 11mg/kg</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Paromomycin</intervention_name>
    <description>11 mg/kg for 14 days</description>
    <arm_group_label>1</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Paromomycin</intervention_name>
    <description>Paromomycin for 21 days @ 11mg/kg by intramuscular injections</description>
    <arm_group_label>1</arm_group_label>
    <arm_group_label>2</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Children and adults, male or female, aged 5 to 55 years, inclusive, who have provided&#xD;
             written informed consent.&#xD;
&#xD;
          -  New or relapsed VL or prior VL treatment failure on a regimen not containing&#xD;
             Paromomycin or AmBisomeÂ®. The diagnosis of VL must be confirmed by a parasite-positive&#xD;
             splenic aspirate.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  LFT greater than 3 times ULN ( AST, ALT, S.Bilirubin, Alkaline Phosphatase, Hb &lt; 4&#xD;
             gm/dl.&#xD;
&#xD;
          -  Platelet &lt;40,000/ mm3&#xD;
&#xD;
          -  Prothrombin Time &gt; 3 Sec. longer than Control.&#xD;
&#xD;
          -  Creatinine &gt; 3 times&#xD;
&#xD;
               -  Normal Value For Male ( 0.6 to 1.1)&#xD;
&#xD;
               -  Normal Value For Female ( 0.5 to 0.9)&#xD;
&#xD;
          -  Absolute Leucocyte count- &lt; 1,000&#xD;
&#xD;
          -  HIV infection&#xD;
&#xD;
          -  Abnormal audiometric and/or vestibular dysfunction&#xD;
&#xD;
          -  History of renal dysfunction&#xD;
&#xD;
          -  Other severe medical conditions&#xD;
&#xD;
          -  History of allergy or hypersensitivity to aminoglycosides&#xD;
&#xD;
          -  Treatment with a parenteral aminoglycoside within 28 days prior to randomisation&#xD;
&#xD;
          -  Previous VL treatment within the past 14 days&#xD;
&#xD;
          -  Previous treatment for VL with paromomycin at any time&#xD;
&#xD;
          -  Pregnancy, lactation, or lack of use of contraception in women of childbearing&#xD;
             potential&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>5 Years</minimum_age>
    <maximum_age>55 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Shyam Sundar, MD</last_name>
    <role>Study Director</role>
    <affiliation>Banaras Hindu University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Kala-azar Medical Research Center, Rambag Road</name>
      <address>
        <city>Varanasi</city>
        <zip>842001</zip>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>India</country>
  </location_countries>
  <verification_date>September 2008</verification_date>
  <study_first_submitted>February 20, 2008</study_first_submitted>
  <study_first_submitted_qc>February 25, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 5, 2008</study_first_posted>
  <last_update_submitted>September 11, 2008</last_update_submitted>
  <last_update_submitted_qc>September 11, 2008</last_update_submitted_qc>
  <last_update_posted type="Estimate">September 12, 2008</last_update_posted>
  <responsible_party>
    <name_title>Shyam Sundar</name_title>
    <organization>Banaras Hindu University</organization>
  </responsible_party>
  <keyword>Visceral leishmaniasis</keyword>
  <keyword>Paromomycin</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Leishmaniasis</mesh_term>
    <mesh_term>Leishmaniasis, Visceral</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Paromomycin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

